Acute Exacerbations in Idiopathic Pulmonary Fibrosis

  1. Seamus P. Crowley, MD;
  2. Peter Kelly, MD, MS; and
  3. Jim J. Egan, MD
  1. From Mater Misericordiae Hospital, Dublin 7, Ireland.

    TO THE EDITOR:

    The data provided by Martinez and colleagues (1) are a further example of the merits of offering treatment to patients with idiopathic pulmonary fibrosis (IPF) only as part of a therapeutic trial. Although the large international study of interferon-γ use in IPF was mostly negative, the data gleaned from the placebo group are critical to our understanding of …

    « Previous | Next Article »Table of Contents